drugset / Trial / NCT00607945
Dietary Fatty Acids As Complementary Therapy in Type 2 Diabetes Mellitus
Phase 1
Completed
48 enrolled
Ohio State University
Bunge Loders Croklaan · collabGlaxoSmithKline · collabLifeScan · collabNational Center for Complementary and Integrative Health (NCCIH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to see how a dietary oil called conjugated linoleic acid, or CLA, might be useful in combination with diabetes medication. Some studies show that CLA can modestly reduce body weight and body fat. Our research idea is that taking CLA will reduce body weight and body fat without interfering with the diabetes medications' effects on blood sugar.
Timeline
- Start
- 2008-01
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Rosiglitazone | Small molecule | 4 mg | — |
| Background | Rosiglitazone | Small molecule | 8 mg | — |